PTAB challenges

Proceedings overview

One AIA trial proceeding has been filed on US patent 7704721. This proceeding, IPR2025-01195, resulted in a discretionary denial of institution, meaning no claims were challenged on the merits. This outcome leaves the patent's claims intact, presenting a hardened defensive posture for the patent owner against future challenges based on the same or similar art/arguments.

IPR2025-01195 — Sarepta Therapeutics, Inc. et al. v. Genzyme Corp.

• Type: Inter Partes Review
• Filed: 2025-06-26
• Status: Discretionary Denial. The Patent Trial and Appeal Board (PTAB) declined to institute a review of the challenged claims, often based on statutory factors or PTAB precedent (e.g., Fintiv factors).
• Judge panel: Information not publicly available in the provided patent text or readily accessible via general search without access to the full PTAB record.
• Petition grounds: The specific claims challenged, prior art references, and statutory bases (§ 102 / § 103 / § 112) are not publicly detailed in the provided patent text. Typically, IPRs focus on § 102 (novelty) and § 103 (obviousness) grounds.
• Institution decision: Denied. While the exact date of the decision is not explicitly stated, the "last modified" date of 2025-12-23 suggests the denial occurred around this time. The denial was "Procedural" and "Discretionary", indicating the Board exercised its discretion not to institute review, likely based on factors such as ongoing district court litigation, timing, or other policy considerations, rather than a full assessment of the merits of the prior art arguments.
• Final Written Decision: Not applicable, as institution was denied.
• Settlement / termination: Not applicable, as the proceeding was terminated by a denial of institution before trial.
• Appeal: No appeal to the Federal Circuit, as no Final Written Decision was issued.
• Defensive value: The patent owner, Genzyme Corp., successfully prevented the institution of an IPR. This means that none of the patent's claims were found unpatentable in this proceeding. For a defendant, this indicates that the specific prior art grounds and arguments raised by Sarepta Therapeutics, Inc. et al. against US7704721 were deemed insufficient or procedurally unsuitable by the PTAB for a full review. Any future IPR petition seeking to challenge the same claims on the same or substantially similar grounds may face estopped arguments or discretionary denial by the Board.

Strategic summary

All 11 claims of US7704721 remain SUSTAINED and UNTESTED on the merits by the PTAB. The single IPR proceeding, IPR2025-01195, was denied institution on discretionary grounds, meaning the PTAB did not reach a decision on the patentability of the claims based on the merits of the prior art. Therefore, there are no claims that have been canceled or held unpatentable through PTAB trial.

The estoppel landscape from IPR2025-01195 is minimal due to the discretionary denial. Under 35 U.S.C. § 315(e)(1), if an IPR is not instituted or terminates before a final written decision, no estoppel applies to the petitioner. However, while statutory estoppel may not apply in the strictest sense for petitioners, the PTAB often considers the arguments previously made in denied petitions when evaluating subsequent petitions (e.g., under General Plastic factors), which could make it harder for the same petitioner (or its privies) to re-file with similar art or arguments. For a new defendant being asserted against, all prior-art grounds are technically still available since no FWD was issued.

Regarding pattern signals, only one IPR has been filed against this patent. The petitioner, Sarepta Therapeutics, Inc. et al., appears to be an operating company rather than a defensive aggregator like Unified Patents, which filed the IPR on behalf of Sarepta. The discretionary denial indicates a victory for the patent owner at the institution stage. There is no pattern of aggressive PTAB appeals by the patent owner, nor multiple IPRs from the same petitioner that proceeded to FWD. The involvement of Unified Patents as the petitioner filing entity suggests a defensive move by a licensee or party seeking to clear the patent.

Recommended next steps

Given that IPR2025-01195 resulted in a discretionary denial of institution, all claims of US7704721 remain valid and undisturbed by this PTAB proceeding. There is no Final Written Decision to link to or quote for claim invalidation. The absence of an instituted trial means that no trial-stage milestones (oral hearing, FWD due date) occurred.

A defendant facing assertion of this patent should be aware that the patent has withstood one IPR attempt without its claims being reviewed on the merits. This denial might suggest strategic considerations the PTAB took into account (e.g., related litigation, patent owner's preliminary response arguments) rather than a definitive statement on the strength of the patent's claims over the prior art. Further analysis would involve:

• Reviewing the full petition and the PTAB's decision on institution for IPR2025-01195 to understand the precise grounds raised and the reasoning behind the discretionary denial. This information would be available through the USPTO PTAB E2E system.
• Conducting a fresh prior art search, as the art presented in the denied IPR may not be exhaustive, and new art could potentially form the basis for a new IPR petition.

https://portal.unifiedpatents.com/ptab/case/IPR2025-01195